Appendix 4E and 2026 Annual Report
Filed with ASX · · 48 pages · English
Summary by 6ix AI
The report highlights a significant loss attributed to the owners of CLEO Diagnostics, with no dividends declared during the financial period. Key achievements include completing a pivotal U.S. clinical trial and expanding the biomarker panel for their Pre-Surgical Ovarian Cancer Test. The company is advancing towards FDA submission and plans to launch its test in the U.S. market, addressing a critical need in ovarian cancer detection.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from CLEO Diagnostics
- CLEO Enters Analytical Validation Phase
- CLEO Establishes U.S. Reimbursement Pathway
- CLEO Commences Kit Manufacturing Ahead of FDA Submission
- Sample Collection Completion for Pivotal US Clinical Trial
- CLEO Optimises Biomarker Panel Ahead of FDA Submission
Later from CLEO Diagnostics
- CLEO Receives First Batch of Commercial Test Kits
- CLIA Certified Lab selected - Pivotal US Clinical Validation
- CLEO Commences Ovarian Cancer Screening Test Development
- Cleo Files Patents for its Ovarian Cancer Screening Test
- CLEO Commences Analytical Validation Ahead of FDA Submission
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics